Revisiting the Amyloid Cascade Hypothesis: From Anti-Aβ Therapeutics to Auspicious New Ways for Alzheimer’s Disease

Emerging Potential of Naturally Occurring Autophagy Modulator against Neurodegeneration

(2020) Md. Ataur Rahman et al.   CURRENT PHARMACEUTICAL DESIGN

Biological signatures of Alzheimer Disease

(2020) Poornima Sharma et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Emerging Promise of Immunotherapy for Alzheimer’s Disease: A New Hope for the Development of Alzheimer’s Vaccine

(2020) Md. Tanvir Kabir et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Neuron‐Glia interaction: Molecular basis of Alzheimer’s Disease and Applications of Neuroproteomics

(2020) Abdallah Mohammad Ibrahim et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

Combination Drug Therapy for the Management of Alzheimer’s Disease

(2020) Md. Tanvir Kabir et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

TV 3326 for Alzheimer’s dementia: a novel multimodal ChE and MAO inhibitors to mitigate Alzheimer’s‐like neuropathology

(2020) Md. Sahab Uddin et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

Exploring the Promise of Targeting Ubiquitin-Proteasome System to Combat Alzheimer’s Disease

(2020) Abdullah Al Mamun et al.   NEUROTOXICITY RESEARCH

Novel Anti-Alzheimer’s Therapeutic Molecules Targeting Amyloid Precursor Protein Processing

(2020) Md. Sahab Uddin et al.   Oxidative Medicine and Cellular Longevity

Evidence Linking Protein Misfolding to Quality Control in Progressive Neurodegenerative Diseases

(2020) Md. Tanvir Kabir et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Exploring the Potential of Neuroproteomics in Alzheimer's Disease

(2020) Md. Sahab Uddin et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Neuroprotective role of polyphenols against oxidative stress-mediated neurodegeneration

(2020) Md Sahab Uddin et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Pharmacological approaches to mitigate neuroinflammation in Alzheimer’s disease

(2020) Md. Sahab Uddin et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Exploring the Role of PSEN Mutations in the Pathogenesis of Alzheimer’s Disease

(2020) Md. Tanvir Kabir et al.   NEUROTOXICITY RESEARCH

A Review on Tramiprosate (Homotaurine) in Alzheimer's Disease and Other Neurocognitive Disorders

(2020) Sagrario Manzano et al.   Frontiers in Neurology

Revisiting the role of brain and peripheral Aβ in the pathogenesis of Alzheimer's disease

(2020) Md. Sahab Uddin et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Alzheimer disease and aducanumab: adjusting our approach

(2019) Dennis J. Selkoe   Nature Reviews Neurology

Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease

(2019) Michael F. Egan et al.   NEW ENGLAND JOURNAL OF MEDICINE

The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis

(2019) Martin Tolar et al.   Alzheimers & Dementia

Cholinesterase Inhibitors for Alzheimer's Disease: Multitargeting Strategy Based on Anti-Alzheimer's Drugs Repositioning

(2019) Md. Tanvir Kabir et al.   CURRENT PHARMACEUTICAL DESIGN

NMDA Receptor Antagonists: Repositioning of Memantine as a Multitargeting Agent for Alzheimer's Therapy

(2019) Md. Tanvir Kabir et al.   CURRENT PHARMACEUTICAL DESIGN

Emerging promise of sulforaphane-mediated Nrf2 signaling cascade against neurological disorders

(2019) Md. Sahab Uddin et al.   SCIENCE OF THE TOTAL ENVIRONMENT

Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer's disease

(2018) Courtney L. Sutphen et al.   Alzheimers & Dementia

Helicobacter pylori and the risk of dementia: A population-based study

(2018) Lana Fani et al.   Alzheimers & Dementia

Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP/PS1/tau mouse model of Alzheimer's disease

(2018) Hong-Yan Cai et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer’s Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study

(2018) Stephen P. Salloway et al.   JOURNAL OF ALZHEIMERS DISEASE

The Aβ protofibril selective antibody mAb158 prevents accumulation of Aβ in astrocytes and rescues neurons from Aβ-induced cell death

(2018) Sofia Söllvander et al.   Journal of Neuroinflammation

The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease

(2018) Andre F Batista et al.   JOURNAL OF PATHOLOGY

Tau-targeting therapies for Alzheimer disease

(2018) Erin E. Congdon et al.   Nature Reviews Neurology

Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums

(2018) Steven E. Arnold et al.   Nature Reviews Neurology

ABBY

(2018) Jeffrey L. Cummings et al.   NEUROLOGY

Tau Kinetics in Neurons and the Human Central Nervous System

(2018) Chihiro Sato et al.   NEURON

Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease

(2018) Michael F. Egan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease

(2018) Yakeel T. Quiroz et al.   JAMA Neurology

Insulin Resistance as a Therapeutic Target in the Treatment of Alzheimer's Disease: A State-of-the-Art Review

(2018) Christian Benedict et al.   Frontiers in Neuroscience

The age of onset and evolution of Braak tangle stage and Thal amyloid pathology of Alzheimer’s disease in individuals with Down syndrome

(2018) Yvonne S. Davidson et al.   Acta Neuropathologica Communications

Role of copper in human neurological disorders

(2018) Vishal Desai et al.   AMERICAN JOURNAL OF CLINICAL NUTRITION

Alzheimer’s Disease (AD) therapeutics - 1: Repeated clinical failures continue to question the amyloid hypothesis of AD and the current understanding of AD causality

(2018) Kevin Mullane et al.   BIOCHEMICAL PHARMACOLOGY

Curcuminoid Binds to Amyloid-β1-42 Oligomer and Fibril

(2018) Daijiro Yanagisawa et al.   JOURNAL OF ALZHEIMERS DISEASE

Gantenerumab: A Novel Human Anti-Aβ Antibody Demonstrates Sustained Cerebral Amyloid-β Binding and Elicits Cell-Mediated Removal of Human Amyloid-β

(2018) Bernd Bohrmann et al.   JOURNAL OF ALZHEIMERS DISEASE

The Murine Version of BAN2401 (mAb158) Selectively Reduces Amyloid-β Protofibrils in Brain and Cerebrospinal Fluid of tg-ArcSwe Mice

(2018) Stina Tucker et al.   JOURNAL OF ALZHEIMERS DISEASE

Is ‘friendly fire’ in the brain provoking Alzheimer’s disease?

(2018) Alison Abbott   NATURE

Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease

(2018) Eric McDade et al.   NEUROLOGY

Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study

(2018) Maarten Timmers et al.   Alzheimers Research & Therapy

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Assessing Safety, Tolerability, and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer’s Disease

(2018) Martin R. Farlow et al.   JOURNAL OF ALZHEIMERS DISEASE

Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer’s Disease

(2017) et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons

(2017) Michael C. Donohue et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer’s Disease Biomarkers: A Pilot Clinical Trial

(2017) Suzanne Craft et al.   JOURNAL OF ALZHEIMERS DISEASE

Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer’s Disease Patients

(2017) Nzeera Ketter et al.   JOURNAL OF ALZHEIMERS DISEASE

Dementia prevention, intervention, and care

(2017) Gill Livingston et al.   LANCET

Amyloid-β plaques enhance Alzheimer's brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation

(2017) Zhuohao He et al.   NATURE MEDICINE

Microglia emerge as central players in brain disease

(2017) Michael W Salter et al.   NATURE MEDICINE

A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease

(2017) Susanne Ostrowitzki et al.   Alzheimers Research & Therapy

Drug Development Based on the Metals Hypothesis of Alzheimer's Disease

(2017) Ashley I. Bush   JOURNAL OF ALZHEIMERS DISEASE

Peripheral Amyloid-β Levels Regulate Amyloid-β Clearance from the Central Nervous System

(2017) Marcos A. Marques et al.   JOURNAL OF ALZHEIMERS DISEASE

PBT2 Rapidly Improves Cognition in Alzheimer's Disease: Additional Phase II Analyses

(2017) Noel G. Faux et al.   JOURNAL OF ALZHEIMERS DISEASE

Intraneuronal aggregation of the β-CTF fragment of APP (C99) induces Aβ-independent lysosomal-autophagic pathology

(2016) Inger Lauritzen et al.   ACTA NEUROPATHOLOGICA

Heterotypic seeding of Tau fibrillization by pre-aggregated Abeta provides potent seeds for prion-like seeding and propagation of Tau-pathology in vivo

(2016) Bruno Vasconcelos et al.   ACTA NEUROPATHOLOGICA

A Role for P-Glycoprotein in Clearance of Alzheimer Amyloid ? -Peptide from the Brain

(2016) Wei Wang et al.   Current Alzheimer Research

AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer’s Disease

(2016) Gvido Cebers et al.   JOURNAL OF ALZHEIMERS DISEASE

AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics

(2016) Susanna Eketjäll et al.   JOURNAL OF ALZHEIMERS DISEASE

Alzheimer's disease

(2016) Philip Scheltens et al.   LANCET

Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study

(2016) Samantha C Burnham et al.   LANCET NEUROLOGY

The adaptive immune system restrains Alzheimer’s disease pathogenesis by modulating microglial function

(2016) Samuel E. Marsh et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The BACE1 inhibitor verubecestat (MK-8931) reduces CNS  -amyloid in animal models and in Alzheimers disease patients

(2016) M. E. Kennedy et al.   Science Translational Medicine

Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody

(2016) Veronika Logovinsky et al.   Alzheimers Research & Therapy

Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy

(2016) Liang Wang et al.   JAMA Neurology

Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community

(2016) Ronald C. Petersen et al.   JAMA Neurology

Stepping closer to treating Alzheimer’s disease patients with BACE1 inhibitor drugs

(2016) Riqiang Yan   Translational Neurodegeneration

Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia

(2015) Willemijn J. Jansen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Soluble amyloid precursor protein alpha inhibits tau phosphorylation through modulation of GSK3β signaling pathway

(2015) Juan Deng et al.   JOURNAL OF NEUROCHEMISTRY

A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease

(2015) R. Scott Turner et al.   NEUROLOGY

Neuroinflammation and Aβ Accumulation Linked To Systemic Inflammation Are Decreased By Genetic PKR Down-Regulation

(2015) Anne-Sophie Carret-Rebillat et al.   Scientific Reports

Targeting Prodromal Alzheimer Disease With Avagacestat

(2015) Vladimir Coric et al.   JAMA Neurology

Amyloid accelerates tau propagation and toxicity in a model of early Alzheimer’s disease

(2015) Amy M Pooler et al.   Acta Neuropathologica Communications

Cerebrospinal Fluid β-Amyloid1–42 Levels in the Differential Diagnosis of Alzheimer’s Disease—Systematic Review and Meta-Analysis

(2015) Jin-A Mo et al.   PLoS One

Elevated risk of type 2 diabetes for development of Alzheimer disease: A key role for oxidative stress in brain

(2014) D. Allan Butterfield et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Inflammation, Defective Insulin Signaling, and Mitochondrial Dysfunction as Common Molecular Denominators Connecting Type 2 Diabetes to Alzheimer Disease

(2014) F. G. De Felice et al.   DIABETES

Repurposing Diabetes Drugs for Brain Insulin Resistance in Alzheimer Disease

(2014) M. Yarchoan et al.   DIABETES

A study on the association between infectious burden and Alzheimer's disease

(2014) X.-L. Bu et al.   EUROPEAN JOURNAL OF NEUROLOGY

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

(2014) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Active immunotherapy options for Alzheimer’s disease

(2014) Bengt Winblad et al.   Alzheimers Research & Therapy

Amyloid-β and Tau

(2014) George S. Bloom   JAMA Neurology

CSF beta-amyloid 1-42 - what are we measuring in Alzheimer's disease?

(2014) William T. Hu et al.   Annals of Clinical and Translational Neurology

Role of Metal Ions in the Self-assembly of the Alzheimer’s Amyloid-β Peptide

(2013) Peter Faller et al.   INORGANIC CHEMISTRY

Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study

(2013) Stephanie JB Vos et al.   LANCET NEUROLOGY

Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study

(2013) Victor L Villemagne et al.   LANCET NEUROLOGY

A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease

(2013) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

BMS-708,163 Targets Presenilin and Lacks Notch-Sparing Activity

(2012) Christina J. Crump et al.   BIOCHEMISTRY

Curcumin's pre-incubation temperature affects its inhibitory potency toward amyloid fibrillation and fibril-induced cytotoxicity of lysozyme

(2012) Kuan-Nan Liu et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

EHT0202 in Alzheimers Disease: A 3-Month, Randomized, Placebo- Controlled, Double-Blind Study

(2012) B. Vellas et al.   Current Alzheimer Research

Chronic Administration of an Aglycosylated Murine Antibody of Ponezumab Does Not Worsen Microhemorrhages in Aged Tg2576 Mice

(2012) Gary B. Freeman et al.   Current Alzheimer Research

Mitochondria-targeted catalase reduces abnormal APP processing, amyloid   production and BACE1 in a mouse model of Alzheimer's disease: implications for neuroprotection and lifespan extension

(2012) P. Mao et al.   HUMAN MOLECULAR GENETICS

Structural Properties of EGCG-Induced, Nontoxic Alzheimer's Disease Aβ Oligomers

(2012) Juan Miguel Lopez del Amo et al.   JOURNAL OF MOLECULAR BIOLOGY

Alzheimer's Disease: Presenilin 2-Sparing  -Secretase Inhibition Is a Tolerable A  Peptide-Lowering Strategy

(2012) T. Borgegard et al.   JOURNAL OF NEUROSCIENCE

An Effector-Reduced Anti- -Amyloid (A ) Antibody with Unique A  Binding Properties Promotes Neuroprotection and Glial Engulfment of A 

(2012) O. Adolfsson et al.   JOURNAL OF NEUROSCIENCE

The  -Secretase-Derived C-Terminal Fragment of  APP, C99, But Not A , Is a Key Contributor to Early Intraneuronal Lesions in Triple-Transgenic Mouse Hippocampus

(2012) I. Lauritzen et al.   JOURNAL OF NEUROSCIENCE

Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study

(2012) Bengt Winblad et al.   LANCET NEUROLOGY

Curcumin Promotes A-beta Fibrillation and Reduces Neurotoxicity in Transgenic Drosophila

(2012) Ina Caesar et al.   PLoS One

Soluble amyloid precursor protein-α modulates β-secretase activity and amyloid-β generation

(2012) Demian Obregon et al.   Nature Communications

Staged decline of neuronal function in vivo in an animal model of Alzheimer's disease

(2012) Christine Grienberger et al.   Nature Communications

Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer's disease

(2012) Sascha Weggen et al.   Alzheimers Research & Therapy

Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study

(2012) John M Ringman et al.   Alzheimers Research & Therapy

Current advances in the treatment of Alzheimer's disease: focused on considerations targeting Aβ and tau

(2012) Yang Hong-Qi et al.   Translational Neurodegeneration

ACS Chemical Neuroscience Molecule Spotlight on ELND006: Another γ-Secretase Inhibitor Fails in the Clinic

(2011) Corey R. Hopkins   ACS Chemical Neuroscience

Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab

(2011) Susanne Ostrowitzki   ARCHIVES OF NEUROLOGY

Rosiglitazone Does Not Improve Cognition or Global Function when Used as Adjunctive Therapy to AChE Inhibitors in Mild-to-Moderate Alzheimers Disease: Two Phase 3 Studies

(2011) C. Harrington et al.   Current Alzheimer Research

Nutritional Approaches to Modulate Oxidative Stress in Alzheimers Disease

(2011) C. B. Pocernich et al.   Current Alzheimer Research

Solanezumab for Alzheimer's disease

(2011) Hossein Samadi et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Structural Basis of C-terminal β-Amyloid Peptide Binding by the Antibody Ponezumab for the Treatment of Alzheimer's Disease

(2011) Sherry L. La Porte et al.   JOURNAL OF MOLECULAR BIOLOGY

Developing β-secretase inhibitors for treatment of Alzheimer’s disease

(2011) Arun K. Ghosh et al.   JOURNAL OF NEUROCHEMISTRY

Inflammation in the early stages of neurodegenerative pathology

(2011) Preeti J. Khandelwal et al.   JOURNAL OF NEUROIMMUNOLOGY

The Second-Generation Active A  Immunotherapy CAD106 Reduces Amyloid Accumulation in APP Transgenic Mice While Minimizing Potential Side Effects

(2011) C. Wiessner et al.   JOURNAL OF NEUROSCIENCE

Resolving controversies on the path to Alzheimer's therapeutics

(2011) Dennis J Selkoe   NATURE MEDICINE

The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics

(2011) Eric Karran et al.   NATURE REVIEWS DRUG DISCOVERY

Different β-amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity

(2011) Fuxiang Bao et al.   NEUROBIOLOGY OF AGING

Resveratrol Protects Rats from Aβ-induced Neurotoxicity by the Reduction of iNOS Expression and Lipid Peroxidation

(2011) Tai-Chun Huang et al.   PLoS One

Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models

(2010) Lars M. Ittner et al.   CELL

ADAM10 is the physiologically relevant, constitutive α-secretase of the amyloid precursor protein in primary neurons

(2010) Peer-Hendrik Kuhn et al.   EMBO JOURNAL

AMP-activated Protein Kinase Signaling Activation by Resveratrol Modulates Amyloid-β Peptide Metabolism

(2010) Valérie Vingtdeux et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Quercetin activates AMP-activated protein kinase by reducing PP2C expression protecting old mouse brain against high cholesterol-induced neurotoxicity

(2010) Jun Lu et al.   JOURNAL OF PATHOLOGY

Can Alzheimer disease be prevented by amyloid-β immunotherapy?

(2010) Cynthia A. Lemere et al.   Nature Reviews Neurology

The secretases: enzymes with therapeutic potential in Alzheimer disease

(2010) Bart De Strooper et al.   Nature Reviews Neurology

Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe

(2010) H. H. Feldman et al.   NEUROLOGY

Decreased Clearance of CNS  -Amyloid in Alzheimer's Disease

(2010) K. G. Mawuenyega et al.   SCIENCE

Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase Inhibitor

(2010) Kevin W. Gillman et al.   ACS Medicinal Chemistry Letters

Results of the first-in-man study with the active Aβ Immunotherapy CAD106 in Alzheimer patients

(2009) Bengt G. Winblad et al.   Alzheimers & Dementia

Beta-secretase as target for amyloid-reduction therapy

(2009) Jordan J.N. Tang   Alzheimers & Dementia

Phenolic Compounds Prevent Alzheimer’s Pathology through Different Effects on the Amyloid-β Aggregation Pathway

(2009) Tsuyoshi Hamaguchi et al.   AMERICAN JOURNAL OF PATHOLOGY

A γ-secretase inhibitor decreases amyloid-β production in the central nervous system

(2009) Randall J. Bateman et al.   ANNALS OF NEUROLOGY

The Role of Metabolic Disorders in Alzheimer Disease and Vascular Dementia

(2009) Suzanne Craft   ARCHIVES OF NEUROLOGY

Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology

(2009) Paula I. Moreira et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Cerebrospinal fluid β-amyloid and dynabridging in Alzheimer’s disease drug development

(2009) Larry Ereshefsky et al.   Biomarkers in Medicine

Involvement of protein trafficking in deprenyl-induced α-secretase activity regulation in PC12 cells

(2009) Hong-Qi Yang et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Dissociated amyloid-β antibody levels as a serum biomarker for the progression of Alzheimer’s disease: A population-based study

(2009) Katarzyna A. Gustaw-Rothenberg et al.   EXPERIMENTAL GERONTOLOGY

Amyloid β and APP as biomarkers for Alzheimer’s disease

(2009) Henrik Zetterberg et al.   EXPERIMENTAL GERONTOLOGY

Biomarkers for Alzheimer’s disease and other forms of dementia: Clinical needs, limitations and future aspects

(2009) Angel Cedazo-Minguez et al.   EXPERIMENTAL GERONTOLOGY

Development of semagacestat (LY450139), a functional γ-secretase inhibitor, for the treatment of Alzheimer's disease

(2009) David B Henley et al.   EXPERT OPINION ON PHARMACOTHERAPY

Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer DiseaseA Randomized Controlled Trial

(2009) Robert C. Green   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Cognitive impairment in nondiabetic middle-aged and older adults is associated with insulin resistance

(2009) H. Bruehl et al.   JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY

Amyloid Reduction by Amyloid-  Vaccination Also Reduces Mouse Tau Pathology and Protects from Neuron Loss in Two Mouse Models of Alzheimer's Disease

(2009) D. M. Wilcock et al.   JOURNAL OF NEUROSCIENCE

Development of AFFITOPE vaccines for Alzheimer’s disease (AD) — From concept to clinical testing

(2009) A. Schneeberger et al.   Journal of Nutrition Health & Aging

 -Secretase Heterogeneity in the Aph1 Subunit: Relevance for Alzheimer's Disease

(2009) L. Serneels et al.   SCIENCE

Phase 2 Safety Trial Targeting Amyloid β Production With a γ-Secretase Inhibitor in Alzheimer Disease

(2008) Adam S. Fleisher et al.   ARCHIVES OF NEUROLOGY

Flavonols and flavones as BACE-1 inhibitors: Structure–activity relationship in cell-free, cell-based and in silico studies reveal novel pharmacophore features

(2008) Yoshiari Shimmyo et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

Memapsin 2 (Beta-Secretase) Inhibitors: Drug Development

(2008) Arun Ghosh et al.   Current Alzheimer Research

The Role of the Cell Surface LRP and Soluble LRP in Blood-Brain Barrier Aβ Clearance in Alzheimers Disease

(2008) R. Deane et al.   CURRENT PHARMACEUTICAL DESIGN

Therapeutic Potential of γ -Secretase Inhibitors and Modulators

(2008) Bruno Imbimbo   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Amyloid plaque imaging in vivo: current achievement and future prospects

(2008) Agneta Nordberg   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Etazolate, a neuroprotective drug linking GABAAreceptor pharmacology to amyloid precursor protein processing

(2008) Maryline Marcade et al.   JOURNAL OF NEUROCHEMISTRY

Protective effect of quercetin in primary neurons against Aβ(1–42): relevance to Alzheimer's disease

(2008) Mubeen Ahmad Ansari et al.   JOURNAL OF NUTRITIONAL BIOCHEMISTRY

Animal models of Alzheimer's disease and frontotemporal dementia

(2008) Jürgen Götz et al.   NATURE REVIEWS NEUROSCIENCE

EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers

(2008) Dagmar E Ehrnhoefer et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Insulin Receptor Signaling Regulates Synapse Number, Dendritic Plasticity, and Circuit Function In Vivo

(2008) Shu-Ling Chiu et al.   NEURON

Rapid Restoration of Cognition in Alzheimer's Transgenic Mice with 8-Hydroxy Quinoline Analogs Is Associated with Decreased Interstitial Aβ

(2008) Paul A. Adlard et al.   NEURON

PPARγ agonists as therapeutics for the treatment of Alzheimer’s disease

(2008) Gary Landreth et al.   Neurotherapeutics

New therapeutic targets in the neurovascular pathway in Alzheimer’s disease

(2008) Berislav V. Zlokovic   Neurotherapeutics

Multifunction of myricetin on Aβ: Neuroprotection via a conformational change of Aβ and reduction of Aβ via the interference of secretases

(2007) Yoshiari Shimmyo et al.   JOURNAL OF NEUROSCIENCE RESEARCH

ADAM-10 over-expression increases cortical synaptogenesis

(2006) Karen F.S. Bell et al.   NEUROBIOLOGY OF AGING

Tyrosine phosphorylation of ionotropic glutamate receptors by Fyn or Src differentially modulates their susceptibility to calpain and enhances their binding to spectrin and PSD-95

(2003) Yongqi Rong et al.   JOURNAL OF NEUROCHEMISTRY

Characterization of Copper Interactions with Alzheimer Amyloid β Peptides

(2003) Craig S. Atwood et al.   JOURNAL OF NEUROCHEMISTRY